JPMorgan Chase & Co. Sells 38,241 Shares of Janux Therapeutics, Inc. $JANX

JPMorgan Chase & Co. decreased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 15.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 209,183 shares of the company’s stock after selling 38,241 shares during the period. JPMorgan Chase & Co. owned 0.35% of Janux Therapeutics worth $5,112,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Osaic Holdings Inc. increased its stake in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares during the period. Winthrop Capital Management LLC acquired a new stake in Janux Therapeutics in the 3rd quarter valued at approximately $106,000. Finally, BNP Paribas Financial Markets grew its holdings in Janux Therapeutics by 185.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after buying an additional 4,982 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $25,798.67. Following the sale, the insider owned 83,095 shares in the company, valued at $1,140,894.35. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 8,072 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. This trade represents a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 19,033 shares of company stock valued at $261,323 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Stock Up 4.4%

Janux Therapeutics stock opened at $14.51 on Thursday. The business has a 50 day moving average price of $13.71 and a two-hundred day moving average price of $19.07. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34. The stock has a market cap of $882.64 million, a price-to-earnings ratio of -7.93 and a beta of 2.81.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $0.08 million. On average, analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the subject of a number of research analyst reports. Guggenheim cut their price target on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a report on Friday, February 27th. Piper Sandler lowered their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Cantor Fitzgerald dropped their target price on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Wall Street Zen cut shares of Janux Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Barclays reduced their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.91.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.